Skip to main content

Month: March 2022

Real Brands Announces Entry to Medical Psychedelics Market, Partners with Marcu & Arora for Licensure, R&D

Real Brands applying for DEA psychedelics licensure Psychedelics drugs market size is projected to reach $10.75 billion by 2027 Real Brands planning to leverage new clinical research to produce and deliver safe, nature-based psychedelics product formulations that will effectively treat mental health conditionsNorth Providence, RI, March 24, 2022 (GLOBE NEWSWIRE) — Real Brands Inc. (OTCQB: RLBD), a multi-brand owner, formulator, extractor and manufacturer of branded hemp-derived CBD products, is initiating expansion to become a premier provider of medical psychedelics. As Phase 1 of laying the groundwork for entry into the medical psychedelics market, Real Brands has entered a partnership with consulting firm Marcu & Arora to apply for U.S. Drug Enforcement Agency (DEA) licensure for psychedelics, including defining the...

Continue reading

Barrick Announces Sale of Shares of Skeena Resources Ltd

TORONTO, March 24, 2022 (GLOBE NEWSWIRE) — Barrick Gold Corporation (“Barrick”) (NYSE:GOLD) (TSX:ABX) announced today that it has entered into a purchase and sale agreement (the “Purchase Agreement”) dated March 23, 2022 with a Canadian investment dealer (the “Dealer”) pursuant to which Barrick agreed to sell, and the Dealer agreed to purchase, 8,831,250 common shares of Skeena Resources Ltd. (“Skeena”) for resale on a bought deal basis, on and subject to the terms and conditions set forth in the Purchase Agreement (the “Disposition”). The gross consideration for the common shares consists of cash in the aggregate amount of C$132,468,750 (C$15.00 per common share). Immediately prior to the closing of the Disposition, Barrick will have beneficial ownership of, or control and direction over, 8,831,250 common shares of Skeena, representing...

Continue reading

Mata Mata Turtle with Squamous Cell Carcinoma Successfully Treated with Sensus Healthcare’s SRT System by Colorado State University Veterinarian

Joins multiple companion animals and a horse successfully treated with SRT BOCA RATON, Fla. , March 24, 2022 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that a mata mata turtle has joined the growing list of animal species successfully treated with Sensus Healthcare’s SRT-100 system.  Tiffany Martin, DVM, MS, Assistant Professor, Radiation Oncology at Colorado State University Veterinary Teaching Hospital applied superficial radiation therapy (SRT) to the turtle’s squamous cell carcinoma in June 2021.  The female turtle, which resides at Denver Zoo, showed no signs of the lesion three months after therapy, and continues to be cancer-free...

Continue reading

HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest

Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” MIRAMAR, Fla., March 24, 2022 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, will participate in Maxim’s 2022 Virtual Growth Conference being held March 28 – 30, 2022. Members of the HCW Biologics’ management team will provide an overview of the Company highlighting the status of its internal pipeline, upcoming milestones for multiple clinical trials for difficult-to-treat cancer indications, and its clinical development strategy to expand to the treatment of other age-related diseases associated with the chronic state of...

Continue reading

Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 31, 2022, to review its financial results for the year ended December 31, 2021 and to provide a Company update. To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 1185595. The live webcast can be accessed under “Presentations, Events & Webcasts” in the Investors section of the Company’s website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. To access the replay, please call (855) 859-2056...

Continue reading

ProStar Announces That One Of America’s Largest Heavy Highway Construction Companies Has Adopted ProStar’s Cloud And Mobile Precision Mapping Solution

GRAND JUNCTION, Colo., March 24, 2022 (GLOBE NEWSWIRE) — ProStar Holdings Inc. (“ProStar®” or “the Company”) (TSXV: MAPS) (OTCQX: MAPPF) (FSE: 5D00), a world leader in Precision Mapping Solutions®, is pleased to announce that Kokosing Construction Company, Inc, one of America’s largest heavy highway construction companies has implemented ProStar’s cloud and mobile solution, PointMan®. “Our focus has always been on placing the best tools and technologies available into our team members’ hands in order to allow everyone on the project site to work more efficiently and safely,” stated Terry Hendershot, General Manager Underground Utilities at Kokosing Construction. “Not knowing the location of underground utilities on a construction project exposes us to major risks and liabilities that can be costly. PointMan helps us to achieve...

Continue reading

Industry leaders to speak at Wood Mackenzie’s European Power & Renewables Conference

Join executives from EDF Energy, Renewable Energy Institute and Société Générale as Europe’s energy sector gears up for critical transformation LONDON/HOUSTON/SINGAPORE, March 24, 2022 (GLOBE NEWSWIRE) — This year looks set to define the European power and renewables sector: an energy market that faces dangerously volatile energy prices, fears of ‘greenflation’ and rising geopolitical risks. As European and national energy regulators, utilities, solar and wind developers and institutional and private investors determine how the renewables sector can evolve over the next decade to meet ambitious emission reduction targets, Wood Mackenzie will host European energy industry leaders at its European Power & Renewables Conference on April 25-26. The hybrid in-person and virtual conference will bring together CEOs, policymakers,...

Continue reading

Meritage Reports Sale of Twisted Rooster Restaurant Concept Opening of New Wendy’s Restaurants

GRAND RAPIDS, Mich., March 24, 2022 (GLOBE NEWSWIRE) — Meritage Hospitality Group, Inc. (OTCQX: MHGU), the nation’s premier franchise restaurant operator, today announced it has closed on the sale of its Twisted Rooster restaurant concept. The sale of the concept will result in a one-time gain of approximately $500,000 and is consistent with the Company’s strategic growth plans to accelerate multi-unit franchise restaurant development. The Company has agreements in place with both its franchisors for the development of newly built restaurants. The Company plans to invest approximately $200.0 million in the development of Wendy’s and Taco John’s restaurants through a combination of cash on hand and development credit facilities. To date in 2022, the Company has opened four of its planned 25 newly built Wendy’s restaurants. “New...

Continue reading

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments

Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase 1b Dose-Esclation Trial Clears 2nd Dose Level and is Now Enrolling 3rd Dose-Level Cohort WILMETTE, Ill., March 24, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced fourth quarter and full-year 2021 financial results and summarized recent program developments. Recent Program Developments and Highlights Validive – International Phase 2b/3 VOICE Clinical Trial, Actively RecruitingValidive is a novel mucobuccal tablet formulation for clonidine that has been designed to provide for prolonged and enhanced local delivery...

Continue reading

Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021 Planned Initiation of INP105 Proof-Of-Concept Study for Autism Spectrum Disorder in First Half of 2022 Recent $100 million Royalty and Debt agreement provides a projected cash runway into 2024 Impel To Host Investor Conference Call Today At 8:30 A.M. ET SEATTLE, March 24, 2022 (GLOBE NEWSWIRE) — Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial results for the fourth quarter and full year ended December 31, 2021, and a corporate update. “We are pleased to see that our targeted and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.